Jan-Lukas Førde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jan-Lukas Førde has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Lars Herfindal
Centre for Pharmacy, Department of Clinical Science, University of Bergen, Norway
3 shared publications Ingeborg Nerbø Reiten
Centre for Pharmacy, Department of Clinical Science, University of Bergen, Norway
2 shared publications- Abdelnour Alhourani
Department of Chemistry, Biosciences and Environmental Engineering, University of Stavanger, Stavanger, Norway
1 shared publication Alexandre Michelet
Applications Development Lab France, PerkinElmer, Villebon-sur-Yvette, France
1 shared publication- Allison L. Creason
Oregon Health & Science University
1 shared publication - Anette Lodvir Hemsing
Department of Medicine, Haukeland University Hospital, pb 1400, Bergen 5021, Norway; Department of Clinical Science, University of Bergen, Jonas Lies vei 87, Bergen 5021, Norway
1 shared publication
Latest Publications
- Open Access
- 6 December 2025
- Published by Elsevier in Translational Oncology
- Vol. 63, 102628
Phenazine 5,10-dioxide analogues as potential therapeutics in AML: Efficacy on patient-derived blasts, in zebrafish larvae xenografts and synergy with venetoclax
- 6 December 2025
- Published by Elsevier in Translational Oncology
- Vol. 63, 102628
Open AccessPhenazine 5,10-dioxide analogues as potential therapeutics in AML: Efficacy on patient-derived blasts, in zebrafish larvae xenografts and synergy with venetoclax
- Open Access
Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response
Background: The tumor microenvironment influences treatment response in ER-positive breast cancer, but what distinguishes responders from non-responders and how it changes during treatment is poorly understood. Methods: ER-positive breast tumors treated with neoadjuvant chemotherapy with or without bevacizumab were profiled with bulk proteomics pre-(n = 95), on-(n = 84) and post-treatment (n = 100). A subset of tumors was profiled with spatial single-cell proteomics pre-(n = 13) and on-treatment (n = 11). Cell phenotypes, spatial location and activation states were determined, and cellular colocalization assessed with spatial metrics. Bulk and spatial features were evaluated against treatment response defined by residual cancer burden. Results: Treatment with bevacizumab amplified chemotherapy effects on proteomic signaling. The immune contexture shifted from suppressive to supportive during treatment through decreased macrophage, regulatory and anergic T-cell density and increased colocalization between epithelial cells and CD8+, CD4+ T-cells and dendritic cells. At baseline, responders had high density of effector memory T-cells, while non-responders had more naïve T-cells. In addition, responders had increased colocalization of epithelial cells with macrophages, and effector memory T-cells with M1-like macrophages compared to non-responders. Conclusions: Spatially distinct tumor-immune microenvironments influence response to neoadjuvant treatment, offering valuable insights for guiding treatment decisions.
Open AccessSpatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response
Background: The tumor microenvironment influences treatment response in ER-positive breast cancer, but what distinguishes responders from non-responders and how it changes during treatment is poorly understood. Methods: ER-positive breast tumors treated with neoadjuvant chemotherapy with or without bevacizumab were profiled with bulk proteomics pre-(n = 95), on-(n = 84) and post-treatment (n = 100). A subset of tumors was profiled with spatial single-cell proteomics pre-(n = 13) and on-treatment (n = 11). Cell phenotypes, spatial location and activation states were determined, and cellular colocalization assessed with spatial metrics. Bulk and spatial features were evaluated against treatment response defined by residual cancer burden. Results: Treatment with bevacizumab amplified chemotherapy effects on proteomic signaling. The immune contexture shifted from suppressive to supportive during treatment through decreased macrophage, regulatory and anergic T-cell density and increased colocalization between epithelial cells and CD8+, CD4+ T-cells and dendritic cells. At baseline, responders had high density of effector memory T-cells, while non-responders had more naïve T-cells. In addition, responders had increased colocalization of epithelial cells with macrophages, and effector memory T-cells with M1-like macrophages compared to non-responders. Conclusions: Spatially distinct tumor-immune microenvironments influence response to neoadjuvant treatment, offering valuable insights for guiding treatment decisions.
- Open Access
- 6 January 2024
- Published by Elsevier in Translational Oncology
- Vol. 40, 101876
The Rac1-inhibitor EHop-016 attenuates AML cell migration and enhances the efficacy of daunorubicin in MOLM-13 transplanted zebrafish larvae
- 6 January 2024
- Published by Elsevier in Translational Oncology
- Vol. 40, 101876
Open AccessThe Rac1-inhibitor EHop-016 attenuates AML cell migration and enhances the efficacy of daunorubicin in MOLM-13 transplanted zebrafish larvae
- 16 December 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 651, 123723
Development of nanoparticles based on amphiphilic cyclodextrins for the delivery of active substances
- 16 December 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 651, 123723
Development of nanoparticles based on amphiphilic cyclodextrins for the delivery of active substances
- Open Access
- 9 February 2022
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 4 (6) , 1668-1680
Graphene-based phenformin carriers for cancer cell treatment: a comparative study between oxidized and pegylated pristine graphene in human cells and zebrafish
Graphene is an attractive choice for the development of an effective drug carrier in cancer treatment due to its high adsorption area and pH-responsive drug affinity.
- 9 February 2022
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 4 (6) , 1668-1680
Open AccessGraphene-based phenformin carriers for cancer cell treatment: a comparative study between oxidized and pegylated pristine graphene in human cells and zebrafish
Graphene is an attractive choice for the development of an effective drug carrier in cancer treatment due to its high adsorption area and pH-responsive drug affinity.